Innovative High Throughput Imaging System

Clearer and Faster Visualization of Disease Markers in Tissue

By | April 16, 2014

Request More Information

PerkinElmer, Inc., a global leader focused on the health and safety of people and the environment, today announced the launch of the Lamina multilabel slide scanner at the USCAP 2014 Annual Meeting. The Lamina scanner is a high throughput imaging system designed to help research pathologists to more easily study protein expression and the relationships between disease markers in formalin-fixed, paraffin-embedded (FFPE) tissue sections. This allows research pathologists to gain a deeper understanding of diseases for the development of more effective therapies and treatments.

Configured to meet the needs of a larger research facility, the Lamina scanner includes high-speed brightfield and fluorescence imaging modalities along with PerkinElmer's proprietary Autofluorescence Reduction Technology (ART™). It is designed to reduce interference from autofluorescence -- an unwanted by-product of tissue fixation -- and fluorophore cross-talk, in which the signal from one fluorophore bleeds into multiple channels. Both of these effects obscure real signals, which can result in an incorrect assessment of a slide. The Lamina scanner delivers these improvements in real-time during whole-slide scanning, enabling clearer visualization of protein biomarker expression in fluorescently labeled tissues. As a result, the Lamina scanner allows users to obtain more accurate information from histological specimens.

"As a leading provider of imaging platforms for disease research, PerkinElmer routinely engages research pathologists globally so we can better understand the complexities of studying disease markers and develop innovative solutions to meet their needs," said Jim Corbett, President, Diagnostics / Life Sciences & Technology, PerkinElmer. "The Lamina scanner can help research pathologists more effectively interpret their images by automating workflows and providing clearer and faster results. These advanced digital pathology capabilities can help lead to a better understanding of disease."

The Lamina scanner produces exceptional-quality, digital, whole-slide images of hematoxylin and eosin, (H&E) immunohistochemistry (IHC) and immunofluorescence-labeled tissue sections and tissue microarrays (TMAs), which can be stored and shared electronically without degradation. The Lamina scanner complements PerkinElmer's comprehensive portfolio of quantitative pathology solutions for translational research, which includes the Vectra® and Nuance®Multispectral imaging systems, inForm® Advanced Image Analysis Software, and biomarker reagent platforms.

Request More Information

Product Details

PerkinElmer Lamina Multilabel Slide Scanner

image of: PerkinElmer Lamina Multilabel Slide Scanner

A Clearer Vision of Pathology

Depth70cm
Height55cm
Weight46kg
Width68cm

Request More Information

Your Request
About You
Enter text from the image above:

Add a Comment

Avatar of: You

You

Processing...
Processing...

Sign In with your LabX Media Group Passport to leave a comment

Not a member? Register Now!

LabX Media Group Passport Logo

Popular Now

  1. UC Berkeley Receives CRISPR Patent in Europe
    Daily News UC Berkeley Receives CRISPR Patent in Europe

    The European Patent Office will grant patent rights over the use of CRISPR in all cell types to a University of California team, contrasting with a recent decision in the U.S.

  2. DNA Replication Errors Contribute to Cancer Risk
  3. Should Healthy People Have Their Exomes Sequenced?
    Daily News Should Healthy People Have Their Exomes Sequenced?

    With its announced launch of a whole-exome sequencing service for apparently healthy individuals, Ambry Genetics is the latest company to enter this growing market. But whether these services are useful for most people remains up for debate.  

  4. Rethinking a Cancer Drug Target
    Daily News Rethinking a Cancer Drug Target

    The results of a CRISPR-Cas9 study suggest that MELK—a protein thought to play a critical role in cancer—is not necessary for cancer cell survival.

Business Birmingham